Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.53 USD | -0.92% | -7.83% | -26.96% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 245.1 | 37.11 | 271 | 216.6 | - | - |
Enterprise Value (EV) 1 | 275.7 | 83.41 | 346 | 239.2 | 260.5 | 275 |
P/E ratio | -4.65 x | -0.78 x | -8.12 x | -6.47 x | -7.52 x | -13 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 5.42 x | 0.82 x | 4.14 x | 2.86 x | 2.43 x | 1.99 x |
EV / Revenue | 6.1 x | 1.83 x | 5.29 x | 3.15 x | 2.92 x | 2.52 x |
EV / EBITDA | -11.8 x | -2.59 x | -19.8 x | -11.8 x | -14.9 x | -22.9 x |
EV / FCF | -11 x | -2.23 x | -17.4 x | -11.2 x | -12.6 x | -19.6 x |
FCF Yield | -9.05% | -44.9% | -5.74% | -8.94% | -7.91% | -5.09% |
Price to Book | 3.35 x | 1.07 x | 13.9 x | 31.9 x | -21.9 x | -9.89 x |
Nbr of stocks (in thousands) | 24,314 | 24,903 | 26,284 | 28,768 | - | - |
Reference price 2 | 10.08 | 1.490 | 10.31 | 7.530 | 7.530 | 7.530 |
Announcement Date | 3/10/22 | 3/2/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 41.14 | 45.18 | 45.52 | 65.42 | 75.86 | 89.25 | 109 |
EBITDA 1 | - | -23.44 | -32.18 | -17.44 | -20.21 | -17.49 | -12.01 |
EBIT 1 | - | -23.74 | -40.79 | -27.17 | -27.13 | -23.86 | -14.2 |
Operating Margin | - | -52.54% | -89.62% | -41.54% | -35.77% | -26.73% | -13.04% |
Earnings before Tax (EBT) 1 | - | -36.08 | -47.08 | -32.96 | -33.23 | -24.4 | -6.7 |
Net income 1 | -24.28 | -36.08 | -47.08 | -32.96 | -33.08 | -29.41 | -17.83 |
Net margin | -59.02% | -79.85% | -103.43% | -50.38% | -43.61% | -32.95% | -16.36% |
EPS 2 | -45.31 | -2.170 | -1.910 | -1.270 | -1.164 | -1.001 | -0.5809 |
Free Cash Flow 1 | - | -24.96 | -37.47 | -19.87 | -21.4 | -20.6 | -14 |
FCF margin | - | -55.24% | -82.32% | -30.38% | -28.21% | -23.08% | -12.85% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/24/21 | 3/10/22 | 3/2/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 11 | 11.37 | 10.2 | 11.16 | 12.79 | 14.47 | 16.51 | 16.43 | 18.01 | 18.12 | 18.3 | 18.83 | 20.68 | 21.37 | 21.19 |
EBITDA 1 | -8.936 | -8.194 | -8.298 | -7.957 | -7.729 | -6.146 | -5.151 | -3.493 | -2.654 | -4.96 | -5.433 | -4.633 | -4.133 | -6 | -6 |
EBIT 1 | -9.015 | -9.762 | -10.97 | -10.2 | -9.859 | -8.319 | -7.854 | -5.95 | -5.051 | -7.545 | -7.508 | -6.687 | -5.59 | -6 | -6 |
Operating Margin | -81.98% | -85.83% | -107.59% | -91.41% | -77.09% | -57.48% | -47.57% | -36.22% | -28.04% | -41.63% | -41.03% | -35.51% | -27.03% | -28.08% | -28.31% |
Earnings before Tax (EBT) 1 | -10.69 | -11.46 | -12.69 | -11.78 | -11.15 | -10.38 | -9.124 | -7.257 | -6.2 | -8.925 | -8.55 | -8.275 | -7.4 | -7 | -8 |
Net income 1 | -10.69 | -11.46 | -12.69 | -11.78 | -11.15 | -10.38 | -9.124 | -7.257 | -6.2 | -8.925 | -8.622 | -8.131 | -7.412 | -8.664 | -8.826 |
Net margin | -97.24% | -100.76% | -124.41% | -105.63% | -87.15% | -71.69% | -55.26% | -44.18% | -34.42% | -49.24% | -47.12% | -43.18% | -35.83% | -40.54% | -41.65% |
EPS 2 | -0.4400 | -0.4700 | -0.5200 | -0.4800 | -0.4500 | -0.4100 | -0.3600 | -0.2800 | -0.2300 | -0.3200 | -0.3069 | -0.2845 | -0.2569 | -0.3100 | -0.3000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/10/22 | 5/12/22 | 8/11/22 | 11/8/22 | 3/2/23 | 5/4/23 | 8/8/23 | 11/6/23 | 3/5/24 | 5/8/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | 30.7 | 46.3 | 75 | 22.6 | 43.9 | 58.4 |
Net Cash position 1 | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | -1.308 x | -1.439 x | -4.3 x | -1.119 x | -2.51 x | -4.859 x |
Free Cash Flow 1 | - | -25 | -37.5 | -19.9 | -21.4 | -20.6 | -14 |
ROE (net income / shareholders' equity) | - | -107% | -87% | -119% | -249% | - | - |
ROA (Net income/ Total Assets) | - | -38.1% | -38% | -29.7% | -33.1% | -37.9% | -28.7% |
Assets 1 | - | 94.76 | 123.8 | 110.9 | 99.8 | 77.64 | 62.08 |
Book Value Per Share 2 | - | 3.010 | 1.390 | 0.7400 | 0.2400 | -0.3400 | -0.7600 |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 0.38 | 0.6 | 0.17 | 2 | 2 | 2 |
Capex / Sales | - | 0.85% | 1.32% | 0.26% | 2.64% | 2.24% | 1.84% |
Announcement Date | 3/24/21 | 3/10/22 | 3/2/23 | 3/5/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.96% | 217M | |
+10.03% | 223B | |
+13.59% | 195B | |
+20.01% | 144B | |
+30.83% | 111B | |
+2.24% | 65.01B | |
+15.38% | 53.02B | |
+3.96% | 50.45B | |
+8.37% | 44.15B | |
+3.27% | 36.45B |
- Stock Market
- Equities
- NPCE Stock
- Financials NeuroPace, Inc.